International Journal of Radiation Oncology*Biology*Physics
Clinical investigation: eyeThe American Brachytherapy Society recommendations for brachytherapy of uveal melanomas
Introduction
Enucleation had been considered the standard treatment for patients with posterior uveal melanoma. In an effort to preserve vision and the globe, episcleral plaque radiotherapy has become a commonly used alternative. Moore first used radon seed brachytherapy to preserve vision for a monocular patient with uveal melanoma (1). Stallard also tried implanting seeds directly into the tumor, but went on to develop cobalt-60 (60Co) plaque radiotherapy (2). Since that time, a number of other radioisotopes (radionuclides), including gold-198, iodine-125, Ru-106/Rh-106, iridium-192, and palladium-103, have been used for episcleral radiotherapy with varying results from retrospective studies 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24. In an effort to resolve some of the controversies, the Collaborative Ocular Melanoma Study (COMS) Group performed a nationwide, multi-institutional, prospective randomized clinical trial to compare efficacy of enucleation vs. I-125 eye plaque radiotherapy for medium-sized choroidal melanomas and recently reported the preliminary results 25, 26. Other than the COMS guidelines, there are no standardized procedures for episcleral eye plaque use. The American Brachytherapy Society (ABS) therefore formed a panel to issue guidelines for the use of brachytherapy for choroidal melanomas.
Section snippets
Methods and materials
Selected members of the ABS with expertise in choroidal melanoma brachytherapy performed a literature review that, supplemented by their clinical experience, allowed formulation of specific recommendations and directions for future investigation in choroidal melanomas. These recommendations were made by consensus opinion and supported by published data whenever possible. In addition, an external multispecialty panel of recognized experts in the field reviewed the consensus recommendations and
Results
Episcleral plaque brachytherapy is a complex procedure, and the ABS recommends that these procedures should only be undertaken in specialized medical centers with expertise in this sophisticated treatment program. The results of the deliberation of the panel and the ABS recommendations are given in the following sections.
Conclusion
Brachytherapy represents an effective means of treating patients with choroidal melanomas. Guidelines are established for the use of brachytherapy in the treatment of choroidal melanomas. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose reporting policies. These guidelines will be modified as further clinical results become available.
Acknowledgements
The authors wish to express their gratitude to Mr. David Carpenter for editorial assistance. The authors acknowledge the support of the Board of Directors of the American Brachytherapy Society and thank Drs. Beth Erickson and Marvin Rotman for their valuable suggestions.
References (120)
Radiation therapy for choroidal melanoma (therapeutic review)
Surv Ophthalmol
(1997)- et al.
Treatment of choroidal melanoma with I-125 plaque
Int J Radiat Oncol Biol Phys
(1993) - et al.
Palladium-103 plaque radiotherapy for choroidal melanoma. An 11-year study
Int J Radiat Oncol Biol Phys
(2002) - et al.
Palladium-103 plaque radiotherapy for uveal melanoma. Clinical experience
Ophthalmology
(1994) - et al.
Palladium-103 plaque radiotherapy for choroidal melanomaResults of a 7-year study
Ophthalmology
(1999) - et al.
The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas
Int J Radiat Oncol Biol Phys
(2001) - et al.
Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture
Ophthalmology
(1993) - et al.
Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma
Int J Radiat Oncol Biol Phys
(2001) Uveal melanoma—Conservative treatment
Hematol Oncol Clin N Am
(2001)- et al.
Visual-field deficits associated with proton beam irradiation for parapapillary choroidal melanoma
Ophthalmology
(1996)
Uveal melanomas near the optic disc or fovea—visual results after proton beam irradiation
Ophthalmol
Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial
Ophthalmology
Ten-year follow-up of helium ion therapy for uveal melanoma
Am J Ophthalmol
Neovascular glaucoma after Helium ion irradiation for uveal melanoma
Ophthalmology
Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma
Radiother Oncol
Episcleral iridium-192 wire therapy for choroidal melanomas
Int J Radiat Oncol Biol Phys
High intensity 125-iodine (125I) plaque treatment of uveal melanoma
Int J Radiat Oncol Biol Phys
Conformal episcleral plaque therapy
Int J Radiat Oncol Biol Phys
Review of eye plaque dosimetry based on AAPM task group 43 recommendations
Int J Radiat Oncol Biol Phys
Physical dosimetry of 125I seeds of a new design for interstitial implant
Int J Radiat Oncol Biol Phys
Dose distributions of model 6702125 seeds in water
Int J Radiat Oncol Biol Phys
Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy
Int J Radiat Oncol Biol Phys
An interactive treatment planning system for ophthalmic plaque radiotherapy
Int J Radiat Oncol Biol Phys
Diode-light transillumination for ophthalmic plaque localization around juxtapapillary choroidal melanomas
Int J Radiat Oncol Biol Phys
Choroidal sarcoma treated by intra-ocular insertion of radon seeds
Br J Ophthalmol
Radiobiology for malignant melanoma of the choroid
Br J Ophthalmol
Brachytherapy for ocular disease
Progress in the use of iodine therapy for tumors of the eye
Br J Radiol
Choroidal melanoma treatment with 125I brachytherapy
Arch Ophthalmol
Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas20 years’ experience
Br J Ophthalmol
Plaque radiotherapy for juxtapapillary choroidal melanoma
Arch Ophthalmol
The use of iodine-125 plaques in the treatment of retinoblastoma
Ophthalmic Paediatr Genet
Iodine-125 irradiation of choroidal melanoma. Clinical experience from the Prince of Wales and Sydney Eye Hospitals
Australas Radiol
Long-term follow-up of iodine-125 brachytherapy for choroidal melanomas. Part IAnatomical results and life expectancy
Eur J Ophthalmol
Radioactive iodine-125 as a therapeutic radiation source for management of intraocular tumors
Trans Am Ophthalmol Soc
Preliminary observations regarding the use of iodine-125 in the management of choroidal melanoma
Trans Ophthalmol Soc UK
Radiotherapy of choroidal melanoma with iodine 125
Int Ophthalmol Clin
Long-term results of iodine 125 irradiation of uveal melanoma
Ophthalmology
Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma
Graefes Arch Clin Exp Ophthalmol
Treatment of juxtapapillary melanomas
Br J Ophthalmol
The COMS randomized trial of Iodine-125 brachytherapy for choroidal melanoma, IIIInitial mortality findings
Arch Ophthalmol
Collaborative Ocular Melanoma Study Randomized Trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report No. 16
Ophthalmology
Lesions mistaken for malignant melanoma of the posterior uveaA clinical pathologic analysis of 100 cases with ophthalmoscopically visible lesions
Arch Ophthalmol
Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1
Arch Ophthalmol
Lesions simulating malignant melanoma of the posterior uvea
Arch Ophthalmol
The persisting pseudomelanoma problem
Arch Ophthalmol
Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6
Am J Ophthalmol
Cited by (200)
GEC-ESTRO survey of <sup>106</sup>Ru eye applicator practice for ocular melanoma – Physicist survey
2024, Radiotherapy and OncologyRecent approaches for the treatment of uveal melanoma: Opportunities and challenges
2024, Critical Reviews in Oncology/HematologySingle-Masked Randomized Phase 2 Study Assessing 2 Forms of Hypofractionated Proton Therapy in Patients With Large Choroidal Melanomas
2023, International Journal of Radiation Oncology Biology PhysicsComparison between dose distribution from <sup>103</sup>Pd, <sup>131</sup>Cs, and <sup>125</sup>I plaques in a real human eye model with different tumor size
2022, Applied Radiation and IsotopesCitation Excerpt :Because of the dose fall-off with respect to depth, the different structures of the eye and the average dose to the tumor are dependent on the tumor apex size. In addition, due to the different energy spectrum of the low-energy sources including 103Pd (with 21 keV average energy), 125I (with 28 keV average energy), and 131Cs (with 30 keV average energy), even if the same dose (85 Gy) to the tumor apex is prescribed, the dose in the tumor and other eye structures will be different for various radioactive sources (Nag et al., 2003). Hence, the dose in the healthy tissue as well as the average dose to the tumor depend on the tumor apex, as a result of the dose fall-off in the medium with distance when considering the same absorbed dose (85 Gy) in the tumor apex.
American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy
2022, BrachytherapyCitation Excerpt :Skin, bone, blood vessel, and major nerve dose constraints are provided in Table 7. Plaque brachytherapy is commonly utilized to treat uveal melanomas with mature cancer control outcomes and visual preservation data available (71–73). Utilizing plaque brachytherapy, rates of local control range from 70% to 96%, though visual acuity may diminish to >20/200 in upwards of 67% of patients (71–76).